Plasma neurofilament light (NFL) has been proposed as a blood-based biomarker for neurodegeneration in Alzheimer’s disease (AD) and parkinsonian disorders. This evidence concerns the gene NEFL and early-onset autosomal dominant Alzheimer disease.